

192
STN

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal626gms

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:32:51 ON 09 SEP 2002

=> s polyvinylpyrrolidone-iodine?

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 15:34:02 ON 09 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 SEP 2002 HIGHEST RN 448182-31-8

DICTIONARY FILE UPDATES: 8 SEP 2002 HIGHEST RN 448182-31-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNnote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s polyvinylpyrrolidone-iodine?

8 POLYVINYLPYRROLIDONE

6804 IODINE?

L1 1 POLYVINYLPYRROLIDONE-IODINE?

(POLYVINYLPYRROLIDONE (W) IODINE?)

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.38	8.80

FILE 'CAPLUS' ENTERED AT 15:34:50 ON 09 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Sep 2002 VOL 137 ISS 11
FILE LAST UPDATED: 8 Sep 2002 (20020908/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l1

L2 1 L1

=> d ibib abs hitstr l2 tot

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1972:479573 CAPLUS

DOCUMENT NUMBER: 77:79573

TITLE: Poly (vinylpyrrolidinone)-iodine compounds

INVENTOR(S): Halpern, Alfred

PATENT ASSIGNEE(S): Synergistics, Inc.

SOURCE: U.S., 6 pp.

CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	US 3671545	A	19720620	US 1969-822008	19690505
AB	Polyhydroxy compds., such as glycerol, propylene glycol, or polyethylene glycols of mol. wt. 200-1000, form hydrogenbonded complexes with a iodophor such as PVP-iodine or nonylphenoxy(ethyleneoxy)ethanol-iodine. These complexes are stable in available I, and are useful as antiseptic agents and in the treatment of acne.				
IT	37330-70-4				
	RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study) (bactericide)				
RN	37330-70-4 CAPLUS				
CN	2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with .alpha.-hydro-.omega.-hydroxypoly(oxy-1,2-ethanediyl) and iodine (9CI) (CA INDEX NAME)				
CM	1				
CRN	25322-68-3				
CMF	(C2 H4 O)n H2 O				
CCI	PMS				



CM 2

CRN 7553-56-2

CMF I2

I-I

CM 3

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 4

CRN 88-12-0

CMF C6 H9 N O



=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.18

13.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.62

-0.62

FILE 'REGISTRY' ENTERED AT 15:36:00 ON 09 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 SEP 2002 HIGHEST RN 448182-31-8

DICTIONARY FILE UPDATES: 8 SEP 2002 HIGHEST RN 448182-31-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Golam Shameem

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s polyvinylpyrrolidone?
L3 8 POLYVINYLPIRROLIDONE?

=> FIL CAPLUS		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.38	18.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.62

FILE 'CAPLUS' ENTERED AT 15:36:37 ON 09 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Sep 2002 VOL 137 ISS 11
FILE LAST UPDATED: 8 Sep 2002 (20020908/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

(FILE 'HOME' ENTERED AT 15:32:51 ON 09 SEP 2002)

FILE 'REGISTRY' ENTERED AT 15:34:02 ON 09 SEP 2002
L1 1 S POLYVINYLPIRROLIDONE-IODINE?

FILE 'CAPLUS' ENTERED AT 15:34:50 ON 09 SEP 2002
L2 1 S L1

FILE 'REGISTRY' ENTERED AT 15:36:00 ON 09 SEP 2002
L3 8 S POLYVINYLPIRROLIDONE?

FILE 'CAPLUS' ENTERED AT 15:36:37 ON 09 SEP 2002

```
=> s 13
L4      19938 L3

=> s 14 and iodine
      107962 IODINE
      182 IODINES
      108038 IODINE
      (IODINE OR IODINES)
L5      987 L4 AND IODINE

=> s 15/proc
      19938 L3
      0 IODINE/CT
      3201546 PROC/RL
      0 IODINE/PROC
      (IODINE/CT (L) PROC/RL)
L6      0 ((L3) AND IODINE/PROC)

=> s 13/proc
      19938 L3
      3201546 PROC/RL
L7      1576 L3/PROC
      (L3 (L) PROC/RL)
```

```
=> d ibib abs hitstr 15 1-25
```

```
L5  ANSWER 1 OF 987  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:      2002:654360  CAPLUS
TITLE:                  Topical compositions containing povidone
                        iodine for the treatment of skin ulcer
INVENTOR(S):           Kikuchi, Yoshiaki; Kanbara, Toshifumi; Hata, Mineo
PATENT ASSIGNEE(S):    Iwaki Seiyaku K. K., Japan
SOURCE:                Jpn. Kokai Tokkyo Koho, 5 pp.
                        CODEN: JKXXAF
DOCUMENT TYPE:         Patent
LANGUAGE:              Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 2002241287	A2	20020828	JP 2001-42979	20010220
AB	The title compns. comprise povidone iodine 0.5-10 % in an nonaq. base contg. saccharide fine powders 60-80 %, sucrose fatty acid esters 0.1-5 %, polyethylene glycol 6-17 %, propylene glycol 1-10 %, and polyoxyethylene stearyl ether 0.1-5 %. The compns. are stable and adhere well on the skin. For example, a topical compn. contained white sugar fine powder 70, povidone iodine 3.2, KI 4, sucrose fatty acid ester (Surfhope Sepharma J-1616) 2.08, lauric acid diethanolamide 2.2, polyethylene glycol-400 15, propylene glycol 3, polyoxyethylene stearyl ether 0.5, and silicone resin 0.02 %.				
IT	INDEXING IN PROGRESS				
IT	25655-41-8, Povidone iodine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(topical compns. contg. povidone iodine in nonaq. base for treatment of skin ulcer)				
RN	25655-41-8 CAPLUS				
CN	2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)				

CM 1


CRN 7553-56-2
CMF I2

I-I

CM 2

CRN 9003-39-8
CMF (C6 H9 N O)x
CCI PMS

CM 3

CRN 88-12-0
CMF C6 H9 N O

L5 ANSWER 2 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:637559 CAPLUS

TITLE: Assembled implants prepared from mixed-composition
segments made of natural bone, alloys, and plastics
INVENTOR(S): Bianchi, John R.; Mills, Randal C.; Gorham, P. J.;
Esch, Michael; Carter, Kevin C.; Coleman, Pat; Ross,
Kevin; Rambo, Harry W.; Jones, Darren G.; Buskirk,
Dayna

PATENT ASSIGNEE(S): Regeneration Technologies, Inc., USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064180	A1	20020822	WO 2001-US27683	20010907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2001031254	A1	20011018	US 2001-782594	20010212

PRIORITY APPLN. INFO.:

US 2001-782594 A 20010212
US 2001-941154 A 20010827
US 1998-191132 A2 19981113
US 2000-181622P P 20000210

AB A method for manuf. of autograft, allograft and xenograft bone implants comprises assembling such implants from smaller pieces of bone graft materials to form a larger graft implant product. One segment of an assembled graft implant is comprised of two or more discrete regions having distinct characteristics and/or properties. An assembled graft implant comprises individual segments fastened together, the segments being mineralized bone, demineralized bone, or a synthetic segment selected from alloys and plastic materials.

IT 25655-41-8, Povidone-iodine

RL: MOA (Modifier or additive use); USES (Uses)
(cleaning soln. contg.; manuf. of assembled implants from mixed-compn. segments made of natural bone, alloys, and plastics)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I-I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



IT 9003-39-8

RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(manuf. of assembled implants from mixed-compn. segments made of natural bone, alloys, and plastics)


RN 9003-39-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 88-12-0

CMF C6 H9 N O



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 3 OF 987 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:615554 CAPLUS
 TITLE: Low-energy carbonylation process for the manufacture of acetic acid from methanol
 INVENTOR(S): Scates, Mark O.; Blay, George A.; Torrence, G. Paull; Broussard, Jerry A.
 PATENT ASSIGNEE(S): Celanese International Corporation, USA
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062740	A1	20020815	WO 2002-US203445	20020206
W: AU, BR, CA, CN, CZ, ID, IN, JP, KR, MX, NO, NZ, PL, RU, SG, TR, TT, UA, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

PRIORITY APPLN. INFO.: US 2001-778663 A 20010207
 AB A low-energy process for producing acetic acid by the carbonylation of methanol is described, which process uses a rhodium-catalyzed system operated at <14% water and utilizing .ltoreq.2 distn. columns. The process is preferably controlled such that the product stream has a low level of propionic acid impurity and the level of aldehyde impurities is minimized by way of aldehyde removal or minimizing aldehyde generation. The level of iodides is controlled by contacting the product, at elevated temps., with ion-exchange resins; at least one silver- or mercury-exchanged macroreticular, strong-acid ion exchange resin is used to purify the product. This high-temp. treatment provides the added benefit of controlling the color value of the acetic acid product steam; process flow diagrams are presented.
 IT 9003-39-8, Polyvinylpyrrolidone
 RL: EPR (Engineering process); PEP (Physical, engineering or chemical process); RGT (Reagent); PROC (Process); RACT (Reactant or reagent) (low-energy carbonylation process for the manuf. of acetic acid from methanol and with iodide removal using)
 RN 9003-39-8 CAPLUS
 CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1


CRN 88-12-0
 CMF C6 H9 N O



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 987 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:615341 CAPLUS
 TITLE: Antimicrobial compositions comprising quaternary ammonium, phenolic, and nitrogen-based heterocyclic compounds
 INVENTOR(S): Falder, Stephen Brian; Rawden, David
 PATENT ASSIGNEE(S): Byotrol LLC, UK
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062142	A1	20020815	WO 2002-GB200010	20020102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			GB 2001-155	A 20010104
			US 2001-756457	A 20010108
AB An anti-microbial compn. comprising (i) a first compd. having a high surface tension of from 20 to 35mN/m, (ii) a second compd. having a low surface tension of from 8 to 14mN/m, (iii) a first anti-microbial agent and (iv) a polar solvent, wherein the compn. acts substantially to prevent the formation of microbial colonies on or at a surface of the compn. IT 9003-39-8D, Polyvinylpyrrolidone, complexes with iodine and triiodine RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (antimicrobial compns. comprising) RN 9003-39-8 CAPLUS CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME) CM 1 CRN 88-12-0 CMF C6 H9 N O				



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:606333 CAPLUS

DOCUMENT NUMBER: 137:145618

TITLE: Topical preparations containing saccharides and iodophors for wound healing

INVENTOR(S): Sato, Toshiaki; Matsuo, Masami

PATENT ASSIGNEE(S): Mikasa Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 2002226381	A2	20020814	JP 2001-22924	20010131
AB	This invention relates to topical prepns. which comprise saccharides, iodophors, polyhydric alcs., and natural gums and show hardness of 1000-50,000 g at 23.degree. and 65 % RH measured by a texture analyzer. The prepns. are molded into a sheet for the treatment of localized tissue injury, burn, wound, etc.				
IT	25655-41-8, Povidone iodine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(topical prepns. contg. saccharides and iodophors for wound healing)				
RN	25655-41-8 CAPLUS				
CN	2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)				
CM	1				
CRN	7553-56-2				
CMF	I2				

I-I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



L5 ANSWER 6 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:559572 CAPLUS

TITLE: Potential anti-inflammatory treatments against cutaneous sulfur mustard injury using the mouse ear vesicant model

AUTHOR(S): Dachir, S.; Fishbeine, E.; Meshulam, Y.; Sahar, R.; Amir, A.; Kadar, T.

CORPORATE SOURCE: Department of Pharmacology, Israel Institute for Biological Research, Ness Ziona, 74100, Israel

SOURCE: Human & Experimental Toxicology (2002), 21(4), 197-203
CODEN: HETOE; ISSN: 0960-3271

PUBLISHER: Arnold, Hodder Headline

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In spite of several decades of research, no effective treatment to skin injuries following exposure to sulfur mustard (HD) has yet been found. In the present study, the mouse ear vesicant model was applied to awake mice in order to evaluate the efficiency of potential anti-inflammatory treatments in preventing HD-induced skin damages. Clin. follow-up and histol. evaluation were used to characterize the injuries to the skin and to evaluate the efficiency of the drugs that were applied. Thus, the extent of mouse ear edema and the histopathol. changes following a single application of 0.2 or 1 .mu.L of neat HD for 10 min (representing moderate and severe lesions, resp.) were monitored. Typical HD skin lesions were obsd. including epithelial and dermal damage. The development of the injury in mouse ears was found to be very similar to that reported in human skin. Screening of post-exposure topical steroids and non-steroidal anti-inflammatory drugs (NSAIDs) proved that HD-induced inflammation could be diminished significantly as long as the treatment was applied during the early stages following exposure. A combined application of these drugs proved to be particularly effective in reducing inflammation.

IT INDEXING IN PROGRESS

IT 25655-41-8, Povidone-iodine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potential anti-inflammatory treatments against cutaneous sulfur mustard injury using mouse ear vesicant model)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2


I- I

CM 2

CRN 9003-39-8
CMF (C6 H9 N O)x
CCI PMS

CM 3

CRN 88-12-0
CMF C6 H9 N O



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:555949 CAPLUS

DOCUMENT NUMBER: 137:113508

TITLE: Methods and apparatus for applying medication of nasal sinuses

INVENTOR(S): Dyer, Gordon Wayne

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 4 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	US 2002098154	A1	20020725	US 2001-765894	20010120
AB	The present invention provides a method and accompanying app. for supplying medications, particularly antibiotics, to the deeper parts areas of the sinuses. The pressure of application from use of the Valsalva maneuver and the use of medications that are both H2O and fat-sol. aids the medications in penetrating deep into the sinuses. When the medication is an antibiotic, this has the benefit of delivering a high level of antibiotics using a line of antibiotics that the likely bacteria will not be as resistant to because they have not had as much prior exposure to this antibiotic. The lighter-than-air propellant aids in delivering the medication to those sinus areas superior to the nose. If the infection extends to the eardrums, making the Valsalva maneuver painful, or if the patient is simply unusually sensitive, then earplugs to reduce the stress on the eardrums may be worn while the patient performs the Valsalva maneuver.				
IT	25655-41-8, Povidone-iodine RL: EPR (Engineering process); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); PROC (Process); USES (Uses) (methods and app. for applying medication of nasal sinuses)				
RN	25655-41-8 CAPLUS				
CN	2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA				

INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I- I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O) x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



L5 ANSWER 8 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:514231 CAPLUS

DOCUMENT NUMBER: 137:68210

TITLE: Topical compositions containing Povidone-
iodine and sugars for restoration of damaged
skin

INVENTOR(S): Hirata, Kenji; Mori, Masaki

PATENT ASSIGNEE(S): Kyowa Yakuhin Kogyo K. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2002193810	A2	20020710	JP 2000-404577	20001222

AB This invention relates to topical compns. for the treatment of damaged skin for bed sore and injuries. The compns. comprise sugars 50-90 %, Povidone-**iodine** 0.5-10 %, and water 1-20 % and are characterized in that they contain gas bubbles of N₂, Ar, CO₂, Ne, or He. The compns. show apparent d. of 0.75-1.25 and are packaged as a sachet, a stick, or a tape. A topical compn. was prepd. contg. refined white sugar 70, Povidone-**iodine** 3, KI 1, polyoxyethylene polyoxypropylene glycol 1.1, Na alginate 1.5, PEG-400 14, glycerin 1, and purified water 8.4 % and air bubbles were introduced to improve the firmness and spreadability of the compn.

IT 25655-41-8, PVP-iodine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical compns. contg. Povidone iodide and sugars for damaged skin
 restoration)
 RN 25655-41-8 CAPLUS
 CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 7553-56-2
 CMF I2

I-I

CM 2
 CRN 9003-39-8
 CMF (C6 H9 N O)x
 CCI PMS
 CM 3
 CRN 88-12-0
 CMF C6 H9 N O



L5 ANSWER 9 OF 987 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:504654 CAPLUS
 DOCUMENT NUMBER: 137:43929
 TITLE: Inspection technique
 INVENTOR(S): Prior, Frank; Heneaghan, Gerry
 PATENT ASSIGNEE(S): Trust Sterile Services Limited, UK
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051451	A1	20020704	WO 2001-GB5609	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,				

TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: GB 2000-31595 A 20001223
 AB The invention relates to a method of and materials for testing for
 material contg. amine groups and therefore for proteins. In particular,
 the method can be used to detect prion proteins.
 IT 9003-39-8, Povidone
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (inspection technique)
 RN 9003-39-8 CAPLUS
 CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 88-12-0

CMF C6 H9 N O



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 987 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:487335 CAPLUS
 DOCUMENT NUMBER: 137:68153
 TITLE: Novel in-situ forming polymer-based controlled release
 microcarrier delivery systems
 INVENTOR(S): Bhagwatwar, Harshal Prabhakar; Bapat, Varada Ramesh;
 Paithankar, Mahesh Balkrishna; Yeola, Bhushan Subhash;
 Gosavi, Arun Shriniwas; Bagool, Manoj Anil; Shetty,
 Nitin; Shukla, Milind Chintaman; De Souza, Noel John;
 Khorakiwala, Habil Fakhruddin
 PATENT ASSIGNEE(S): India
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049573	A2	20020627	WO 2001-IN219	20011214
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2000-256319P P 20001218

AB A ready-to use, stable, gelled polymer droplet-in-oil dispersion is described which helps in in-situ formation of a multitude of small solid, semisolid, or gelled microcarriers. The dispersion is placed into a body in a semisolid form and cures to form the delivery system in-situ. The process for making such a dispersion comprises the steps of (i) dissolving a polymer in a biocompatible solvent at an elevated temp. to form a polymer soln., (ii) prepg. a second oil phase soln. of a biocompatible emulsifier at an elevated temp., (iii) mixing the polymer soln. with the oil phase soln. at an elevated temp. and subsequently cooling to refrigeration temp. Placing the gelled dispersion within a body produces the microcarrier delivery system in-situ. The compn. of a syringeable, biodegradable dispersion incorporating an effective level of a biol. active agent before injection into a body provides a novel controlled delivery system of drugs for health-care applications. Thus, Poly(DL-lactide-co-glycolide) was dissolved in DMSO to form a polymer soln. of a 30% wt./wt. concn. To this soln. was added leuprolide acetate to form a 10% wt./wt. soln. of the drug with respect to the polymer. The polymer soln. was injected by into a continuous oil phase comprising a 20% wt./wt. soln. of sorbitan monostearate (Arlacel 60) in super refined sesame seed oil maintained at 70-75.degree., accompanied by high speed homogenization at 13,000 rpm, for 3 min. The resulting polymer droplet-in-oil dispersion was cooled to room temp. with continuous mixing to obtain an opaque mass with a gel-like consistency, which did not flow. The gel was stored under refrigerated conditions until further use. The gel was smooth to the touch with an absence of any gritty particles. Microscopic observation of the gel revealed discrete distorted blue colored droplets of the discontinuous phase dispersed within the continuous oil phase.

IT 9003-39-8, Polyvinylpyrrolidone 25655-41-8, Povidone iodine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in-situ forming polymer-based controlled release microcarrier delivery systems)


RN 9003-39-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 88-12-0

CMF C6 H9 N O



RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2


I- I

CM 2

CRN 9003-39-8
CMF (C6 H9 N O) x
CCI PMS

CM 3

CRN 88-12-0
CMF C6 H9 N O



L5 ANSWER 11 OF 987 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:479964 CAPLUS
DOCUMENT NUMBER: 137:37686
TITLE: Saccharide esters for promotion of wound healing
INVENTOR(S): Sakaguchi, Ikuyo; Ikeda, Kiwa; Minamino, Miki; Kato, Takayoshi
PATENT ASSIGNEE(S): Club Cosmetics Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	JP 2002179575	A2	20020626	JP 2000-377472	20001212
AB	This invention relates to the use of C30-40 fatty acid esters with monosaccharides or disaccharides or acid-fast bacterial cell exts. contg. the esters, for the promotion of wound healing. Also claimed is a topical pharmaceutical contg. the esters and antimicrobials. Rhodococcus sp. 4306 was fermented and collected cells were extd. using CHCl ₃ /MeOH. Mycolic acid esters with trehalose, glucose, mannose, and fructose were identified in a lipid fraction. Trehalose 6,6'-dimycolate (TDM) showed a wound-healing effect in animal studies. Ointments, pastes, and creams contg. TDM were formulated.				
IT	25655-41-8, Povidone iodine RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical pharmaceuticals contg. saccharide esters and antimicrobials for promotion of wound healing)				
RN	25655-41-8 CAPLUS				
CN	2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)				

CM 1

CRN 7553-56-2
CMF I2


I-I

CM 2

CRN 9003-39-8
CMF (C6 H9 N O) x
CCI PMS

CM 3

CRN 88-12-0
CMF C6 H9 N O



L5 ANSWER 12 OF 987 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:466548 CAPLUS
DOCUMENT NUMBER: 137:52372
TITLE: Multiple phase matrix compositions containing
crosslinked polymers for controlled drug release
INVENTOR(S): Stein, Stanley; Qiu, Bo
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002076443	A1	20020620	US 2001-883842	20010618

PRIORITY APPLN. INFO.: US 2000-212511P P 20000619

AB Pharmaceutical compns. comprise a cross-linked matrix phys. entrapping at least one therapeutic agent. The matrix comprises a homogeneous mixt. of aq. phase and at least one other phase, such as a solid and/or oil phase, and at least one crosslinked polymer. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have addnl. profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each addnl. therapeutic agent may have one or more controlled release in-vivo kinetic profile. For example, quinine sulfate monohydrate was entrapped in a thiol-contg. polymer hydrogel through an emulsion system. A thiol-contg. polymer (16 mg), prepd. from .alpha.,.omega.-dihydroxy-PEG and thiomalic acid, was dissolved in 200 .mu.L of PBS, pH 7.4. To this, 200 .mu.L of Et myristate was added as the oil phase and 24 mg of sodium dodecyl sulfate as the emulsifier. The

mixt. was mixed thoroughly to form an emulsion system. Fifty mg of quinine sulfate monohydrate was added into the above emulsion system. Then, 4.7 mg PEG-divinyl sulfonate was dissolved in 100 mL of PBS, pH 7.4. After thorough mixing in a 1.5 mL Eppendorf tube, the mixt. was allowed to stand at room temp. until the hydrogel was formed.

IT 9003-39-8, Polyvinyl pyrrolidone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multiple phase matrix compns. contg. crosslinked polymers for controlled drug release)


RN 9003-39-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 88-12-0

CMF C6 H9 N O



L5 ANSWER 13 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:429292 CAPLUS

DOCUMENT NUMBER: 137:11054

TITLE: Embalming fluids containing iodine-based disinfectants

INVENTOR(S): Barrow, Dermot Christopher John

PATENT ASSIGNEE(S): UK

SOURCE: U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002066168	A1	20020606	US 2001-809433	20010316
WO 2002043484	A2	20020606	WO 2001-GB5337	20011203

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2000-29410 A 20001201

AB An embalming fluid is provided which is free from formaldehyde. The preferred disinfectant is an iodine-based disinfectant, polyvinylpyrrolidone-iodine being particularly preferred. Embalming methods are also disclosed, together with kits for use in prepg. an embalming fluid in accordance with the invention and concd. forms of the fluid. A method of embalming comprises injecting to the body which is

to be embalmed a fluid free of formaldehyde, and which comprises: (a) a vegetable-based, water-sol. polymer; (b) a non-toxic disinfectant which is free from formaldehyde; and (c) demineralized water, optionally with conventional additives, e.g. one or more perfumes and colorants.

IT 25655-41-8

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(embalming fluids contg. iodine-based disinfectants)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I- I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



L5 ANSWER 14 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:421801 CAPLUS

DOCUMENT NUMBER: 136:398379

TITLE: Evaluation of factors responsible for transmission of Legionella pneumophila. Optimum temperature range, heat resistance, susceptibility to disinfectants, and pathogenicity in mice

AUTHOR(S): Li, Xiu Hua

CORPORATE SOURCE: Coll. Health Professions, Toho Univ., Tokyo, Japan

SOURCE: Kyorin Igakkai Zasshi (2002), 33(1), 23-32

CODEN: KIZSB8; ISSN: 0368-5829

PUBLISHER: Kyorin Igakkai

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Using clin. isolates of Legionella pneumophila and those isolated from the environment, their optimum temp. range for growth, heat resistance, and susceptibility to disinfectants were investigated to ascertain if there was any difference in the factors enhancing their transmission. In addn.,

exptl. animals (mice) were used to find whether the state of host resistance affects the transmission or development of the disease. It was found that the temp. at which the bacteria failed to grow was below 20.degree. or above 39.degree., with no outstanding difference between the clin. isolates and those isolated from the environment. The optimum temp. range was 31.3 to 32.0.degree.. The Legionella pneumophila has been cultured at 35.degree. but the present test indicated that a temp. range of 31 to 32.degree. is optimum. At a heat treatment at 60.degree. for 5 min all test strains survived, while only 9 of the 13 strains survived the treatment that lasted for 10 min. When treated at 65.degree. for 5 min, 2 of the 13 strains survived, however, no strain survived the treatment that lasted for 10 min. The clin. isolates were only slightly more resistant to heat than the environmental isolates. The min. killing concn. (MKC) was found for each disinfectant at concns. below the level at which each agent is normally used. Sodium hypochlorite exhibited the lowest MKC, followed by povidone-iodine, glutaral, and benzalkonium chloride, in ascending order. For all disinfectants, the duration of application was inversely to the MKC. None of the strains exhibited resistance to these disinfectants. Compared with normal mice, anti-mouse potency expressed as a 5000 lethal dosage (LD50) was smaller in the cyclophosphamide- or hydrocortisone-treated mice. No significant difference was noted between the clin. and the environmental isolates.

IT 25655-41-8, Povidone-iodine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(factors responsible for transmission of Legionella pneumophila)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I- I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



L5 ANSWER 15 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:416457 CAPLUS

DOCUMENT NUMBER: 137:90635

TITLE: Antimicrobial Effectiveness of Povidone-Iodine
and Consequences for New Application AreasAUTHOR(S): Reimer, K.; Wichelhaus, T. A.; Schaefer, V.; Rudolph,
P.; Kramer, A.; Wutzler, P.; Ganzer, D.; Fleischer, W.

CORPORATE SOURCE: Mundipharma GmbH, Limburg, Germany

SOURCE: Dermatology (Basel, Switzerland) (2002), 204 (Suppl.
1), 114-120

CODEN: DERAEG; ISSN: 1018-8665

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. The microbicidal action spectrum of povidone-iodine (PVP-I) is broad - even after short onset times. Unlike local antibiotics and other antiseptic substances, no resistance develops. The high degree of bactericidal efficiency in respect of highly resistant gram-pos. pathogenic micro-organisms, such as methicillin-resistant *Staphylococcus aureus* (MRSA) and enterococcus strains, is particularly significant for hospital hygiene. An in vitro study with 10 genotypically different MRSA isolates showed an optimum bactericidal effect (logarithmic redn. factor value >5) without protein load after just 30 s exposure and even in a diln. of Betaisodona soln. (Mundipharma GmbH) of 1%. With protein load (0.2% albumin), the optimum in microbicidal effectiveness shifts to concns. >0.1% Betaisodona soln. referring to an exposure time of 30 s. Since recent results are now also available on the toxicol. safety of PVP-I preps. for the ciliated epithelium of the nasal mucosa and the good tolerability on skin and other mucous membranes is a known factor, a controlled clin. study is currently being carried out to eliminate colonizations of MRSA. Evidence has also recently been produced of the antiviral activity of PVP-I against herpes simplex, adeno- and enteroviruses, as well as its high degree of efficiency against Chlamydia. Hence alongside the classical fields of application, such as the disinfection of the skin and hands, mucosa antiseptics and wound treatment, there are also useful indications for the substance, i.e. rinsing of body cavities and joints and application to the eye.

IT 25655-41-8, Povidone-Iodine

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)(antimicrobial effectiveness of povidone-iodine and
application)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA
INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I- I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:416456 CAPLUS

DOCUMENT NUMBER: 137:15344

TITLE: In vitro Evaluation of Skin Sensitivity of Povidone-Iodine and Other Antiseptics Using a Three-Dimensional Human Skin Model

AUTHOR(S): Nagasawa, Mieko; Hayashi, Hiroyuki; Nakayoshi, Takemi
CORPORATE SOURCE: Pharmaceutical Research Center, Meiji Seika Kaisha, Yokohama, Japan

SOURCE: Dermatology (Basel, Switzerland) (2002), 204 (Suppl. 1), 109-113

CODEN: DERAEG; ISSN: 1018-8665

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Povidone-iodine (PVP-I) is an antiseptic which has been widely used in various fields. It was reported to have a weaker skin irritancy than other antiseptics in the Draize skin irritation test using rabbits. Recent increased concern for animal welfare requires us to use skin models in the tests as an alternative to animal testing. Actually, there are some skin models already commercialized, which are available to evaluate skin irritancy caused by e.g. chem. reagents, cosmetics or medicines. In this study, we evaluated the potential of a PVP-I soln. and other antiseptics to cause irritation using a cultured human skin model (three-dimensional skin model) under conditions similar to clin. use. This skin model has two layers like a real skin, such as the dermis and epidermis which includes the cornified layer. For the evaluation of skin irritancy in this model, cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as an endpoint. Antiseptic formulations such as benzalkonium chloride (BAC), benzethonium chloride (BEC), chlorhexidine gluconate (CHG) and alkylldiaminoethylglycine hydrochloride (AEG) were used in this study. As a result, PVP-I showed a significantly weaker skin irritancy compared to the other antiseptics. The present in vitro study results revealed a correlation with the results of previously conducted in vivo skin irritancy tests using rabbits.

IT 25655-41-8, Isodine

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(in vitro evaluation of skin sensitivity of povidone-iodine and other antiseptics using three-dimensional human skin model)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I-I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:416455 CAPLUS

DOCUMENT NUMBER: 137:15343

TITLE: Investigation of Irritant Skin Reaction by 10% Povidone-Iodine Solution after Surgery

AUTHOR(S): Iijima, Shigeruko; Kuramochi, Miyako

CORPORATE SOURCE: Department of Dermatology, Mito Saiseikai General Hospital, Ibaraki, Japan

SOURCE: Dermatology (Basel, Switzerland) (2002), 204 (Suppl. 1), 103-108

CODEN: DERAEG; ISSN: 1018-8665

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We report 19 patients who developed extensive patchy or linear erythema on both sides of the buttocks, the back and the posterior areas of the thighs within a few days following operations or cardioangiog. The erythema was sometimes deeply infiltrative and was also accompanied by bullae and erosion. Patch tests of the patients were strongly pos. for 10% povidone-iodine (PVP-I, Isodine.RTM.) soln.; however, they were neg. for 10% PVP-I soln. with the same amt. of 8% sodium thiosulfate and for 5% potassium iodide in petrolatum. In all control individuals, the only pos. result was that of a patch test with 10% PVP-I soln. within 8 h after application. We diagnosed our patients as having irritant contact dermatitis caused by 10% PVP-I soln. during the procedure, which might

have drained along the skin to the side of the buttocks or the back. We here indicate that prolonged contact with a large quantity of 10% PVP-I soln. should be avoided to prevent this problem.

IT 25655-41-8

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(irritant skin reaction by 10% povidone-iodine soln. after surgery)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I- I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:416454 CAPLUS

DOCUMENT NUMBER: 137:15342

TITLE: Thyroid Function in Nurses: The Influence of Povidone-Iodine Hand Washing and Gargling

AUTHOR(S): Nobukuni, Keigo; Kawahara, Shin

CORPORATE SOURCE: Department of Neurology, Clinical Research Institute, National Minami-Okayama Hospital, Okayama, Japan

SOURCE: Dermatology (Basel, Switzerland) (2002), 204 (Suppl. 1), 99-102

CODEN: DERAEG; ISSN: 1018-8665

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effect of povidone-iodine (PVP-I) hand washing and gargling on thyroid function was assessed. In 16 nurses using PVP-I products and

16 control subjects, serum inorg. **iodine** levels and thyroid functions were investigated. The status of PVP-I use was also surveyed in the nurses. Clin. symptoms considered to be attributable to thyroid dysfunctions were seen in none of the subjects, nor was a goiter obsd. in any of the subjects. In nurses, serum inorg. **iodine** levels were slightly increased as compared to those in the control subjects, although the difference was not significant. The **iodine** incorporated during working hours of nurses appears to be attributable to gargling rather than to hand washing. The long-term use of PVP-I for gargling should be avoided by (1) people with a high risk of developing thyroid dysfunction due to the excessive intake of **iodine**, (2) pregnant women and (3) breast-feeding mothers.

IT 25655-41-8, Povidone-Iodine

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(influence of povidone-**iodine** hand washing and gargling on thyroid function in nurses)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I- I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:416439 CAPLUS

TITLE: In vitro Antiseptic Susceptibility of Clinical Isolates from Nosocomial Infections

AUTHOR(S): Shimizu, M.; Okuzumi, K.; Yoneyama, A.; Kunisada, T.; Araake, M.; Ogawa, H.; Kimura, S.

CORPORATE SOURCE: Pharmaceutical Research Center, Meiji Seika Kaisha

SOURCE: Ltd., Yokohama, Japan
Dermatology (Basel, Switzerland) (2002), 204 (Suppl. 1), 21-27
CODEN: DERAEG; ISSN: 1018-8665
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To evaluate the susceptibility of a large no. of strains to various antiseptics, we elaborated a simple, qual. broth turbidity method in which we could quickly judge the efficacy visually. For this method, we prepd. a modified neutralizer broth, consisting of trypticase soy broth contg. 15% Tween 80, 1% soybean lecithin and 0.5% sodium thiosulfate. The susceptibilities of *Serratia marcescens* No. 26 to 4 antiseptics obtained from the turbidity method showed a good agreement with those obtained from the colony-counting method; the 4 antiseptics tested were povidone-iodine (PVP-I), chlorhexidine gluconate (CHG), benzalkonium chloride (BAC) and alkyldiaminoethylglycine hydrochloride (AEG). Both PVP-I and BAC had complete efficacy in 0.5 min against all isolates tested [100 isolates of *S. marcescens*, 103 of *Klebsiella pneumoniae*, 99 of *Pseudomonas aeruginosa*, 19 of *Alcaligenes fecalis* and 30 of *A. xylosoxidans* subsp. *Alcaligenes xylosoxidans* (*A. xylosoxydans*)]. In contrast, the effectiveness of CHG was weak compared with PVP-I, BAC and AEG. Strong resistance against AEG was noted even after 3-min exposure in 1 isolate each of *A. fecalis* and *A. xylosoxydans*. It is concluded that the turbidity test is a simple and accurate method to evaluate susceptibility to various antiseptics and that it is suitable for a screening of a large no. of strains. Among the 4 antiseptics tested, PVP-I and BAC showed a consistently high activity against all isolates, confirming PVP-I and BAC to be clin. useful antiseptics.

IT INDEXING IN PROGRESS

IT 25655-41-8, Povidone-iodine

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(in vitro antiseptic susceptibility of clin. isolates from nosocomial infections)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I-I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:416438 CAPLUS

TITLE: Bactericidal Activities of Commonly Used Antiseptics against Multidrug-Resistant Mycobacterium tuberculosis
AUTHOR(S): Rikimaru, T.; Kondo, M.; Kajimura, K.; Hashimoto, K.; Oyamada, K.; Sagawa, K.; Tanoue, S.; Oizumi, K.

CORPORATE SOURCE: Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan

SOURCE: Dermatology (Basel, Switzerland) (2002), 204 (Suppl. 1), 15-20

CODEN: DERAEG; ISSN: 1018-8665

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Seventeen clin. isolates of Mycobacterium tuberculosis were selected in order to study the bactericidal activities against drug-resistant M. tuberculosis. The effects of different antiseptics against multidrug-resistant M. tuberculosis (MDR-TB) were examd. Each of the test strains was cultured on the surface of an agar slant contg. Loewenstein-Jensen medium. 0.05 mL of the bacillary suspension was poured into a test tube, and 0.45 mL of various antiseptics was added. After the bacilli had been exposed to the antiseptic soln. with 2% human serum for various periods of incubation time, the antiseptic was inactivated by addn. of 0.45 mL neutralizer, a mixt. contg. 10% Tween 80, 3% soybean lecithin and 0.5% sodium thiosulfate. As the results, povidone-iodine (PVP-I) at a concn. of 0.2% killed 99.9% or more of all strains tested within 30 s. All of the strains tested with PVP-I were killed almost completely within 60 s. There was no difference in bactericidal activities of PVP-I between std. strain H37Rv and MDR-TB. 99.9% or more of all strains tested were killed after exposure to 1.0% cresol for 60 s. In the case of cresol however, the exposure time of 30 s was not enough to get satisfactory effects. 2.0% glutaraldehyde needed 5 min to kill 99.99% or more of the bacilli tested, and 0.2% alkylldiaminoethylglycine hydrochloride required 60 min to do so. The results of bactericidal activities of common antiseptics against MDR-TB were similar to those against H37Rv. We conclude that the com. available PVP-I product is a useful antiseptic against MDR-TB similar to other M. tuberculosis.

IT INDEXING IN PROGRESS

IT 25655-41-8

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activities of antiseptics against multidrug-resistant Mycobacterium tuberculosis)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I-I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:412340 CAPLUS

DOCUMENT NUMBER: 136:374812

TITLE: Agent for treatment of cows with mastitis

INVENTOR(S): Gavrish, V. G.; Egunova, A. V.; Novikova, S. V.;
Zhukov, O. I.

PATENT ASSIGNEE(S): Zakrytoe Aktsionernoe Obshchestvo "Nita-Farm", Russia

SOURCE: Russ., No pp. given

CODEN: RUXXE7

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2165261	C1	20010420	RU 2000-104660	20000224

AB An agent for treatment of cows with mastitis contains an **iodine** org. compd. as an active component and distd. water as a solvent and has an addnl. hydrophilic gel base including, for example, poloxomer or polyvinyl alc., phosphate-citrate buffer and glycerol. Iodopolyvinylpyrrolidone is taken as an active substance in the following ratio of components, wt.-%: iodopolyvinylpyrrolidone, 1-10; poloxomer or polyvinyl alc., 5-20; phosphate-citrate buffer, 0.3-20; glycerol, 25-50 and distd. water, the balance. The invention provides increased content of active substance and its rapid and uniform distribution in udder tissue due to the presence of the gel-like base. The invention provides enhancement of antibacterial, antifungal, anti-inflammatory, wound-healing and other effects, decrease of residual symptoms and adverse effects and practical absence of irritant effect of **iodine** in tissues. The invention can be used as agent for treatment of cows with mastitis and for

treatment of surgery diseases of skin and mucous tissues.

IT 25655-41-8

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(iodinated agent for treatment of cows with mastitis)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I- I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



L5 ANSWER 22 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:403803 CAPLUS

DOCUMENT NUMBER: 136:406861

TITLE: Hydrophilic polymer blends used to prevent cow skin infections

INVENTOR(S): Ehrhard, Joseph; Eknoian, Michael; Vinci, Alfredo

PATENT ASSIGNEE(S): Hydromer, Inc., USA

SOURCE: U.S., 8 pp., Cont.-in-part of U.S. 6,203,812.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6395289	B1	20020528	US 2000-557716	20000425
US 6203812	B1	20010320	US 1998-106680	19980629
US 6440442	B1	20020827	US 2000-706677	20001106
PRIORITY APPLN. INFO.:			US 1998-106680	A2 19980629

US 2000-557716 A2 20000425

AB The invention discloses a mammalian teat dip for controlling mastitis, a method for prepg. the compn. and a method of treatment of mammals. The compn. contains a film-forming polymer blend, at least one antimicrobial and a sodium bicarbonate buffering agent. The polymer blend contains a solvent-sol., thermoplastic polyurethane and a hydrophilic poly(N-vinyl lactam). Upon application to mammalian skin, this compn. leaves a long-lasting, water-resistant, residual, elastic film that treats and protects mammalian skin from infection. To 89.5 g of water was added 0.5 g of xanthan gum with stirring, the soln. was then mixed until homogeneous. Then, 5.0 g of a hydrophilic polymer (a blend of thermoplastic polyurethane and poly(N-vinyl lactam)) was added with stirring until homogeneous. Next, 5.0 g of an aq. **iodine** soln. was added and the soln. was mixed and pH adjusted to approx. 5.5. The soln. has a typical **iodine** color and does not drip when cast onto a plate and held vertically, and films cast from the resulting soln. are elastic and water-resistant which prevents the spread of mastitis causing organisms. Microbial barrier properties of the teat dip was tested.

IT 25655-41-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hydrophilic polymer blends used to prevent cow skin infections)

RN 25655-41-8 CAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I-I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 987 CAPLUS COPYRIGHT 2002 ACS

Golam Shameem

ACCESSION NUMBER: 2002:381237 CAPLUS
DOCUMENT NUMBER: 136:374877
TITLE: Wet tissue-type topical drug delivery systems, and
method for applying the same
INVENTOR(S): Aratani, Yoshimitsu; Mikami, Ikuko; Yahagi, Ichiro
PATENT ASSIGNEE(S): Pigeon Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	JP 2002145762	A2	20020522	JP 2000-344166	20001110
AB	The invention provides a wet tissue-type topical drug delivery system having an base fabric sheet contg. a drug in wet condition, suitable for applying the drug without direct touch. An absorbent cotton sheet (130 .times. 99 mm) contg. diphenhydramine hydrochloride 1, benzalkonium chloride 0.4, 1,3-butylene glycol 6, ethanol 2, Me paraben 0.15, Et paraben 0.1, and water balance to 100 % was prepd., folded to a size of 33 .times. 65 mm, and packaged in a PET/Al/polypropylene laminated plastic pouch.				
IT	25655-41-8, Povidone iodine RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (wet tissue-type topical drug delivery systems contg. antihistamine agents, antimicrobial agents, and wetting agents)				
RN	25655-41-8 CAPLUS				
CN	2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)				
CM	1				
CRN	7553-56-2				
CMF	I2				


I- I

CM 2

CRN 9003-39-8
CMF (C6 H9 N O) x
CCI PMS

CM 3

CRN 88-12-0
CMF C6 H9 N O



L5 ANSWER 24 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:373155 CAPLUS

DOCUMENT NUMBER: 136:345774

TITLE: Iodine-based bactericidal gel

INVENTOR(S): Bicalho, Sheyla Maria de Castro Maximo

PATENT ASSIGNEE(S): J H S Laboratorio Quimico Ltda, Brazil

SOURCE: Braz. Pedido PI, 5 pp.

CODEN: BPXXDX


DOCUMENT TYPE: Patent

LANGUAGE: Portuguese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	BR 9904673	A	20010605	BR 1999-4673	19991025
AB	An iodine-based bactericidal gel is disclosed which has the appearance of a gelatinous paste. The iodized base comprises iodized alc. contg. 1.5% polymer, 10% PVP-1, 70% ethanol, deionized water 18.5%. The gel base contains 1.5% polyacrylate, 10% PVP-1, 20% sodium sulfate lauryl ether, and deionized water 68.5%.				
IT	9003-39-8, Pvp RL: PEP (Physical, engineering or chemical process); POF (Polymer in formulation); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (iodine-based bactericidal gel)				
RN	9003-39-8 CAPLUS				
CN	2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)				
CM	1				
CRN	88-12-0				
CMF	C6 H9 N O				



L5 ANSWER 25 OF 987 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:364208 CAPLUS

DOCUMENT NUMBER: 136:374919

TITLE: Contact lens cleansers comprising disinfectants

INVENTOR(S): Saito, Fumio; Kikuchi, Satoru; Yasuba, Masako

PATENT ASSIGNEE(S): Offtecs K. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

JP 2002139715 A2 20020517 JP 2001-215419 20010716
 PRIORITY APPLN. INFO.: JP 2000-218048 A 20000718
 AB This invention relates to contact lens cleansing and disinfecting preps. comprising (1) a soln. contg. **iodine**-type disinfectants, protein-degrading enzymes, nonreducing polyhydric alcs., iodides, and Ca compds.; (2) a solid neutralizer contg. reducing agents; and (3) an aq. soln. contg. buffers, isotonic agents, and/or chelates for solubilization. A contact lens cleanser comprised (1) a soln. contg. povidone **iodine**, subtilisin, glycerin, borax, boric acid, and KI, and CaCl₂.cntdot.2H₂O; (2) a tablet contg. Na sulfite, Poloxamer, Na₂CO₃, citric acid, lactose, and HEC; and (3) a soln. contg. NaCl, Na₂EDTA, boric acid, borax, and water.
 IT **25655-41-8, Povidone iodine**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (contact lens cleansers comprising disinfectants)
 RN 25655-41-8 CAPLUS
 CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9CI) (CA INDEX NAME)

CM 1

CRN 7553-56-2

CMF I2

I- I

CM 2

CRN 9003-39-8


CMF (C6 H9 N O)x

CCI PMS

CM 3

CRN 88-12-0

CMF C6 H9 N O



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

119.80

138.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION


CA SUBSCRIBER PRICE

-15.49

-16.11

STN INTERNATIONAL LOGOFF AT 15:41:45 ON 09 SEP 2002

Golam Shameem



vinylpyrrolidone-iodine